Highlights Newsletter 3

This newsletter presents you the following key sessions:

1. PODCAST with prof. Arnon Kater about undetectable minimal residual disease in relapsed/refractory chronic
    lymphocytic leukemia patients following fixed-duration venetoclax-rituximab therapy

2. First-line ibrutinib-venetoclax allows for treatment-free remissions in patients with chronic lymphocytic
    leukaemia obtaining minimal residual disease negativity

3. Blinatumomab: a new standard in the consolidation therapy for children with high-risk acute lymphoblastic
    leukaemia patients in first relapse

4. Ibrutinib-rituximab demonstrates sustained superiority over rituximab alone in patients with Waldenström’s
    macroglobulinaemia

5. Gilteritinib plus azacitidine: an effective alternative to intensive induction chemotherapy in newly diagnosed
    acute myeloid leukaemia patients harbouring a FLT3 mutation?